Abstract
Neurodegenerative diseases may directly affect memory performance, thus leading to functional impairments. An increasing body of evidence suggests an association between dietary intake of omega-3 fatty acids and memory functioning in animal models as well as in human studies. Recent evidence supports a potential beneficial role of omega-3 fatty acid supplementation on psychopathological and cognitive symptoms, beside their established positive effects on cardiovascular health.
Objective: We summarize relevant and recent evidence from epidemiological, interventional and experimental studies investigating dietary consumption of omega-3 fatty acids and emphazing mechanisms of memory disorders, with a focus on mild cognitive impairment (MCI) and dementia. Omega-3 fatty acid could represent an affordable and accessible adjunctive treatment option to improve cognitive and non-cognitive function with a focus on MCI or dementia. However, apart from its translational promise, which is based on mechanistic models and evidence from animal studies, evidence for clinical benefits in humans is lacking. Method: To follow this research question, a search through electronic databases for the following search terms to identify relevant studies was conducted: ‘omega 3 fatty acids’, ‘cognition’, ‘memory’, ´Alzheimer´s Disease ´, ´dementia´, ´MCI`. Studies were included if they presented original data and were published in English between 1990 and 2015. Results: To our the best of our knowledge, there are only 8 interventional studies that investigated the effects of n3-PUFAs in dementia patients, while 6 studies were conducted in healthy individuals, which in combination show equivocal results. Conclusion: This verifies the need for larger and (more) well designed clinical trials.Keywords: Omega 3 fatty acids, psychiatric disorders, cognition, Alzheimer's dementia, MCI.
Current Alzheimer Research
Title:Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia
Volume: 14 Issue: 3
Author(s): Christian Knöchel, Martin Voss, Florian Gruter, Gilberto S. Alves, Silke Matura, Beate Sepanski, Michael Stablein, Dominik Kraft, David Prvulovic, Andre F. Carvalho, Andreas Reif and Viola Oertel-Knochel
Affiliation:
Keywords: Omega 3 fatty acids, psychiatric disorders, cognition, Alzheimer's dementia, MCI.
Abstract: Neurodegenerative diseases may directly affect memory performance, thus leading to functional impairments. An increasing body of evidence suggests an association between dietary intake of omega-3 fatty acids and memory functioning in animal models as well as in human studies. Recent evidence supports a potential beneficial role of omega-3 fatty acid supplementation on psychopathological and cognitive symptoms, beside their established positive effects on cardiovascular health.
Objective: We summarize relevant and recent evidence from epidemiological, interventional and experimental studies investigating dietary consumption of omega-3 fatty acids and emphazing mechanisms of memory disorders, with a focus on mild cognitive impairment (MCI) and dementia. Omega-3 fatty acid could represent an affordable and accessible adjunctive treatment option to improve cognitive and non-cognitive function with a focus on MCI or dementia. However, apart from its translational promise, which is based on mechanistic models and evidence from animal studies, evidence for clinical benefits in humans is lacking. Method: To follow this research question, a search through electronic databases for the following search terms to identify relevant studies was conducted: ‘omega 3 fatty acids’, ‘cognition’, ‘memory’, ´Alzheimer´s Disease ´, ´dementia´, ´MCI`. Studies were included if they presented original data and were published in English between 1990 and 2015. Results: To our the best of our knowledge, there are only 8 interventional studies that investigated the effects of n3-PUFAs in dementia patients, while 6 studies were conducted in healthy individuals, which in combination show equivocal results. Conclusion: This verifies the need for larger and (more) well designed clinical trials.Export Options
About this article
Cite this article as:
Knöchel Christian, Voss Martin, Gruter Florian, Alves S. Gilberto, Matura Silke, Sepanski Beate, Stablein Michael, Kraft Dominik, Prvulovic David, Carvalho F. Andre, Reif Andreas and Oertel-Knochel Viola, Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666160602235520
DOI https://dx.doi.org/10.2174/1567205013666160602235520 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Ameliorative Effect of Trans-Sinapic Acid and its Protective Role in Cerebral Hypoxia in Aluminium Chloride Induced Dementia of Alzheimer's Type
CNS & Neurological Disorders - Drug Targets Causes and Diagnosis of Alzheimers Disease: A Proteomics Approach
Current Proteomics Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design Origins, Controversies and Recent Developments of the MCI Construct
Current Alzheimer Research Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Protective Substances Against Zinc-Induced Neuronal Death after Ischemia:Carnosine as a Target for Drug of Vascular Type of Dementia
Recent Patents on CNS Drug Discovery (Discontinued) Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain
CNS & Neurological Disorders - Drug Targets Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study
Current Alzheimer Research Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes
Current Enzyme Inhibition Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry The Effects of Exposure to Recent Autobiographical Events on Declarative Memory in Amnestic Mild Cognitive Impairment: A Preliminary Pilot Study
Current Alzheimer Research Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity
Current Protein & Peptide Science 1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Mini-Reviews in Medicinal Chemistry Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: Anti-Amyloidogenic/Protein-Misfolding Therapies in Amyloidosis and Other Protein-Misfolding Disorders (Executive Editor: Masahito Yamada)]
Current Pharmaceutical Design Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Recent Patents on Drugs Addressing Neurodegenerative Diseases
Recent Patents on Biomarkers